Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Portal Vein Thrombosis

Author: Hrishikesh Samant Author: Kwabena O. Asafo-Agyei Author: Ali Kimyaghalam Editor: Karen Garfield Updated: 4/19/2024 2:26:22 PM

Introduction

Portal vein thrombosis (PVT) is a narrowing or blocking of the portal vein by a blood clot. Thrombosis can develop in the main body of the portal vein or its intrahepatic branches and may even extend to the splenic or superior mesenteric veins. PVT frequently occurs with cirrhosis of the liver but may also occur without an associated liver disease like malignancy, abdominal sepsis, or pancreatitis. The extrahepatic portal venous obstruction terminology should be considered a separate entity that refers to developing portal cavernoma or collaterals around chronic portal vein thrombosis.

The portal venous system, originating from the vitelline venous system, close to the umbilical venous system, from the fourth to the twelfth weeks of gestation, drains blood from the gastrointestinal tract (excluding the lower third of the rectum) and biliopancreatic apparatus, including the spleen, pancreas, and gallbladder, to the liver.[1][2]

The veins that drain the gastrointestinal organs parallel the major arteries that supply the foregut, midgut, and hindgut, including the celiac, superior mesenteric, and inferior mesenteric arteries, respectively. These veins eventually convene at the portal vein, forming a single venous inflow tract into the liver. The celiac vein drains the foregut structures, including the stomach, through the second part of the duodenum. The superior mesenteric vein drains the third part of the duodenum through the initial two-thirds of the transverse colon. The inferior mesenteric vein drains the remaining one-third of the transverse colon through the rectum. These veins comprehensively drain nutrients and toxins from the digestive intake and ultimately provide approximately 75% of the liver's blood supply, with the remaining blood coming from the hepatic artery—eventually draining into the hepatic veins and systemic circulation.[1][3]

The portal vein forms the confluence of the splenic and superior mesenteric veins, draining the spleen and small intestine, respectively. Portal vein occlusion with thrombosis formation typically occurs in 2 main groups of patients: patients with cirrhosis and patients with prothrombotic disorders. Acute PVT occurs with abrupt thrombotic portal vein occlusion. Portal vein thrombosis can result in complete or partial occlusion of the vein and consequent clot propagation into the mesenteric and splenic tributaries. Features of chronic PVT, such as collateral circulation (eg, cavernous portal transformation) or portal hypertension, have not developed in acute PVT. If the patient's knowledge of when the clot developed is unknown and the patient does not have features of chronic PVT, the PVT can be referred to as being "recent."[1] Managing recent PVT is the same as managing acute PVT.

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

The most common cause of PVT is cirrhosis; in a non-cirrhotic liver, PVT is mainly due to inherited or acquired pro-thrombotic states. Primary myeloproliferative disorders are the most common procoagulant state found. Other pro-thrombotic conditions that cause PVT include paroxysmal nocturnal hemoglobinuria, antiphospholipid syndrome, hyperhomocysteinemia, inherited pro-thrombotic disorders such as protein C, S, and antithrombin III deficiencies, and less frequently, factor V Leiden mutation, factor II mutation, and methylenetetrahydrofolate reductase gene mutation.[4] 

Rare conditions associated with PVT are pregnancy, chronic inflammatory diseases, oral contraceptives, and malignancies with or without the above pro-thrombotic causes.[5] Malignancy is responsible for PVT in approximately 25% of cases.

Intra-abdominal inflammatory conditions leading to vascular endothelial injury can cause PVT. These include pancreatitis, cholangitis, appendicitis, and liver abscesses. Local injury to the portal venous axis following splenectomy, laparoscopic colectomy, or abdominal trauma with the above acquired or inherited pro-thrombotic conditions can lead to PVT.

The etiology of extrahepatic portal venous obstruction (EHPVO) in children is phlebosclerosis, with thrombosis as a secondary event. Omphalitis, neonatal umbilical sepsis, umbilical vein cannulation, repeated abdominal infections, sepsis, abdominal surgery, and trauma later progress to EHPVO.[6]

Collectively, the etiological factors for portal vein thrombosis can be categorized as follows:

  • Complications of abdominal surgeries, including but not limited to bariatric surgeries [7][8]
  • Vascular thrombotic complications of Behçet's syndrome [9] 
  • Cirrhosis [10]
  • Collagen vascular disease, including systemic lupus erythematosus, with rheumatoid arthritis, polymyositis and dermatomyositis, systemic sclerosis, mixed connective tissue disease, and polyarteritis nodosa [11]
  • Malignancies, including hepatocellular carcinoma and pancreatic cancer with and without identified thrombophilic risk factors [12]
  • Iatrogenic following endoscopic sclerotherapy [13]
  • Inflammatory bowel disease-related PVT [14]
  • Inherited thrombophilia, including factor V Leiden and PTG20210A mutation [15]
  • Myeloproliferative disease and related thrombophilia [16]
  • Omphalitis and portal vein thrombosis [17]
  • Oral contraceptive drugs [18]
  • Total pancreatectomy with islet autotransplantation [19]
  • Acute pancreatitis [20]
  • Paroxysmal nocturnal hemoglubinuria [21]
  • Pregnancy [22]
  • Retroperitoneal fibrosis [23]
  • Transjugular intrahepatic portosystemic shunt [24]
  • Portal vein thrombosis following trauma [25]

Epidemiology

The prevalence of PVT in cirrhosis has been reported to be 0.6% to 16% and is more common in patients awaiting liver transplantation. PVT is in up to 35% of patients with cirrhosis and hepatocellular carcinoma. The lifetime risk of PVT in the general population is 1%.[26] A systematic review and meta-analysis evaluated 8549 papers to probe the epidemiology of portal vein thrombosis in patients with cirrhosis. The PubMed, Excerpta Medica Database, and Cochrane Library databases were included. Fifty-four studies evaluated the prevalence of PVT in patients with cirrhosis, and a prevalence of 13.92% was reported. (95% confidence interval= 11.18%–16.91%).[27] Factors associated with a higher risk of portal vein thrombosis in patients with cirrhosis include Child-Pugh class B/C, higher levels of D-dimer, history of non-selective beta-blockers intake, patients at risk for moderate to severe esophageal varices, and presence of ascites.[27]

Pathophysiology

The pathophysiology of portal vein thrombosis encompasses 1 or more features of Virchrow triad, which include reduced portal blood flow, a hypercoagulable state, or vascular endothelial injury. A confluence of splenic and superior mesenteric veins forms a portal vein, which carries blood from the spleen and small intestine to the liver. Patients with cirrhosis usually have slow blood flow through the severely scarred liver. These altered portal hemodynamics are more likely to produce clots and can cause portal vein thrombosis. Malignant portal vein obstruction occurs by direct vascular invasion by hepatocellular carcinoma, and cholangiocarcinoma or compression by tumor mass or lymph node are the other potential mechanisms involved.

The underlying pathophysiological mechanism involved in portal vein thrombosis can be categorized into 2 major conditions: inherited and acquired.[28][29][30]

Inherited thrombophilia conditions associated with PVT include the following principal reasons:

  • Factor V Leiden mutations [31]
  • Prothrombin G20210A mutations [31][32]
  • Protein C deficiency [33]
  • Protein S deficiency [31][34]
  • Antithrombin deficiency [35] 
  • Elevated factor VIII levels
  • Mutations in the methylenetetrahydrofolate reductase gene [36]

Acquired thrombophilia conditions associated with PVT include the following:

  • Complications of abdominal surgeries, including but not limited to bariatric surgeries [7][8]
  • Vascular thrombotic complications of Behçet syndrome [9]
  • Cirrhosis [10]
  • Collagen vascular disease, including systemic lupus erythematosus, with rheumatoid arthritis, polymyositis and dermatomyositis, systemic sclerosis, mixed connective tissue disease, and polyarteritis nodosa [11]
  • Malignancies, including hepatocellular carcinoma and pancreatic cancer with and without identified thrombophilic risk factors [12]
  • Iatrogenic following endoscopic sclerotherapy [13]
  • Inflammatory bowel disease-related PVT [14]
  • Inherited thrombophilia, including factor V Leiden and PTG20210A mutation [15]
  • Myeloproliferative disease and related thrombophilia [16]
  • Omphalitis and portal vein thrombosis [17]
  • Oral contraceptive drugs [18]
  • Total pancreatectomy with islet autotransplantation [19]
  • Acute pancreatitis [20]
  • Paroxysmal nocturnal hemoglubinuria [21]
  • Pregnancy [22]
  • Retroperitoneal fibrosis [23]
  • Transjugular intrahepatic portosystemic shunt [24]
  • Portal vein thrombosis following trauma [25]

History and Physical

Portal vein thrombosis is asymptomatic in a majority of patients. Clinically, PVT may be acute or chronic, although no time frame exists to distinguish acute from chronic. Portal hypertension develops due to chronic obstruction to the flow within the portal venous system. Portal hypertension can present with left upper quadrant abdominal fullness due to splenomegaly or upper gastrointestinal (GI) bleeding from esophageal or gastric varices.

Non-cirrhotic, non-malignant acute PVT usually presents with abdominal pain (91%), fever (53%), and ascites (38%).[37] Extension of portal vein thrombus into a superior mesenteric vein may lead to intestinal ischemia, bowel infarction, and ileus presenting as hematochezia, fever, and sepsis and is responsible for high mortality in this subset of patients. 

If new portal vein thrombosis develops in people with cirrhosis, they present with hepatic decompensation in ascites, jaundice, or variceal bleeding. In patients with underlying cirrhosis, ascites usually develop when large amounts of fluids are given intravenously to treat massive bleeding from ruptured esophageal or gastric varices. Patients with EHPVO present with only portal hypertension-related complications like a well-tolerated upper GI bleed, splenomegaly, anemia, and thrombocytopenia, or they may be asymptomatic with incidental detection following an imaging procedure.

Evaluation

Liver Function Tests

The liver functions are normal or near normal unless PVT occurs in a patient with cirrhosis. Portal hypertension due to chronic PVT may cause thrombocytopenia due to splenomegaly. Patients with portal biliopathy may show a rise in alkaline phosphatase and bilirubin.

Doppler Ultrasound

Doppler ultrasound is an investigation of choice with sensitivity and specificity ranging from 80% to 100% with 88% to 98% accuracy. The Doppler ultrasound will show solid isoechoic or hypoechoic material within the portal vein, partially or entirely filling the lumen without reduced portal venous flow. Portal cavernoma will be seen as multiple tortuous small vessels replacing the portal vein, which is suggestive of chronic PVT. Ultrasound will also pick up associated with splenomegaly. Contrast-enhanced ultrasound and endoscopic ultrasound are other modalities that are superior to ultrasound in demonstrating the presence or absence of flow in the portal vein when it is very small.

Computed Tomography and Magnetic Resonance Imaging

Computed tomography (CT) and magnetic resonance imaging (MRI) provide additional information, such as the extension of the thrombus, evidence of bowel infarction, and the status of adjacent organs. A CT scan with contrast also helps distinguish a bland thrombus from a malignant one. A bland thrombus is typically seen as a low-density, non-enhancing defect within portal veins. In contrast, a tumor thrombus enhances following contrast administration with distension of the vessel wall or intra-thrombus contrast enhancement due to neovascularization. The sensitivity and specificity of MRI for detecting the main PVT are 100% and 98%, respectively and is valuable in determining the resectability of neoplasm involving the portal venous system and follow-up after therapeutic procedures.[38] Positron emission tomography CT also has been shown to help differentiate benign and malignant portal vein obstruction.

Splenoportovenography

This is an invasive but obsolete procedure done in the past, involving injecting dye into the splenic pulp and visualizing the splenoportal venous axis that helped in diagnosing PVT and identifying the patency of the splenoportal axis for future splenorenal or mesocaval shunt surgery. In the pre-ultrasound/CT/MRI era, it was proven to be a safe procedure that also helped measure portal pressure.

Endoscopy

An endoscopy is essential in patients with PVT, as portal hypertensive gastropathy is often present in acute PVT with cancer or cirrhosis. Large ectopic/esophageal/gastric varices are present more frequently in patients with chronic PVT.

Procoagulant Workup

Once the diagnosis of PVT is made, an extensive investigation of prothrombotic disorders and local factors is recommended, including antiphospholipid syndrome, protein C, S, antithrombin III levels, factor V, and Leiden mutation, among others.

Treatment / Management

Anticoagulation

The treatment aims to reverse or prevent the advancement of thrombosis in the portal venous system and to treat complications of established PVT. There is a clear recommendation for using anticoagulation in non-cirrhotic acute PVT with reasonable safety and efficacy data for low molecular weight heparin and new oral anticoagulants. However, the data on cirrhosis is limited.

Anticoagulation is indicated with impending intestinal ischemia, decompensated liver disease awaiting liver transplantation, and a compensated liver disease with a new diagnosis of acute PVT or PVT with asymptomatic mesenteric venous occlusion. In contrast, anticoagulation in non-transplant candidates with advanced liver disease and patients with portal cavernoma formation without thrombotic risk factors may not benefit survival. Enoxaparin was safe, with no significant side effects or hemorrhagic events in cirrhosis. There is still insufficient data on newer oral anticoagulants in cirrhosis, as most are metabolized in the liver.

Thrombolysis

Thrombolytic therapy in recent non-cirrhotic portal vein thrombosis can be done via indirect intra-arterial infusion of tissue plasminogen activator, urokinase, or streptokinase into the superior mesenteric artery (SMA) or directly via the catheter introduced into a portal vein either transhepatically or through the transjugular approach.[39] 

However, prolonged catheterization of SMA may pose a risk of embolizing SMA and its arterial branches. Hence, direct access to the portal vein via the transjugular or percutaneous intrahepatic route is the preferred mode as being less time-consuming and a more efficient technique with a requirement of a reduced dose of thrombolytics, thereby reducing the thrombolysis-related complications.

Thrombectomy

Surgical thrombectomy or mechanical thrombectomy by percutaneous transhepatic route is associated with the recurrence of thrombosis from intimal or vascular trauma to the portal vein.[40] Percutaneous transhepatic thrombo-aspiration within 72 hours has been done successfully in some patients.

Transvenous Intrahepatic Portosystemic Shunt

Transvenous intrahepatic portosystemic shunt placement in the setting of portal vein thrombosis is technically challenging for radiologists. However, when placed successfully, there is a possibility of achieving recanalization by disrupting the thrombus and mechanical thrombectomy. The management of acute portal vein thrombosis should be initiated with anticoagulation therapy. However, the treatment of predisposing factors should not be underestimated.[41]

The main and essential objective of the treatment is to limit clot extension and to provide the optimal environment for clot recanalization.[41][42] Notwithstanding the significant impact of managing acute portal vein thrombosis with anticoagulant therapy, anticoagulant therapy's direct role and effectiveness in patients with chronic PVT are yet to be established.[6] Anticoagulation should be triggered with low molecular weight heparin, and the ultimate goal should be switching to warfarin or directly-acting oral anticoagulation. The goal of treatment is to maintain an international normalized ratio (INR) of 2 to 3.[43]

Moreover, a group of patients with cirrhosis may have esophageal varices. Therefore, screening the esophageal varices should be prioritized before starting the medical management with anticoagulation therapy.[44] The level of impact and risk-benefit of anticoagulation in patients with chronic portal vein thrombosis and cirrhosis is yet to be established. However, the studies have shown comparable outcomes for patients with and without thrombosis.[45](B2)

The results from several studies were suggestive of downregulated treatment efficacy with factor Xa inhibitors, including rivaroxaban, and direct factor Xa inhibitors, including apixaban.[46] Moreover, studies demonstrated a relative bleeding risk between natural factor Xa inhibitors and conventional treatments.[47] Accordingly, further investigations are required to provide an evidence-based recommendation for treating acute PVT with natural factor Xa inhibitors.(B2)

Considering the treatment duration, 3 to 6 months is generally recommended. However, more prolonged treatment should be considered for most patients with inherited underlying thrombophilia disorders.[48] Moreover, the extended portal vein thrombosis with mesenteric vein involvement should be managed with a longer duration of anticoagulation. The latter circumstances harbor the risk of intestinal infraction. Patient care should be individualized since the INR does not necessarily reflect the level of anticoagulation management with non-warfarin medication.(A1)

Differential Diagnosis

Differential diagnosis of this condition includes:

  • Arsenic toxicity 
  • Budd-Chiari syndrome 
  • Cirrhosis
  • Sarcoidosis
  • Schistosomiasis [49]

Prognosis

In acute non-cirrhotic portal vein thrombosis, with an early diagnosis, improved diagnostic techniques, and early anticoagulation, the 5-year survival rate has now improved to 85%. Mortality is primarily due to an underlying cause or as a consequence of portal hypertension. Acute PVT usually has a good prognosis if it does not progress to intestinal infarction.

In chronic extrahepatic portal vein thrombosis, bleeding-related mortality is much lower due to preserved liver function compared to cirrhosis. In contrast, in portal vein thrombosis in a patient with cirrhosis, the 2-year survival is reduced by 55%, secondary to hepatic dysfunction.[50]

Complications

Portal Hypertension

Portal hypertension is responsible for most complications in patients with chronic PVT. It presents with splenomegaly, varices, or ascites. Portal vein thrombosis commonly forms varices in sites other than the esophagus and stomach (ectopic varices).

Intestinal Ischemia

Intestinal ischemia is typically seen when acute PVT progresses to obstruction of the mesenteric venous outflow with reflex arterial constriction and occlusion.

Septic Portal Vein Thrombosis

Septic portal vein thrombosis (acute pylephlebitis) occurs when PVT develops in a patient with an abdominal focus of infection, such as appendicitis and diverticulitis.

Portal Cholangiopathy

Portal cholangiopathy is a complication that may develop with longstanding PVT due to extrinsic compression of large bile ducts from venous collaterals around the portal vein, and it may progress to ischemic strictures of bile ducts, presenting obstructive jaundice and cholangitis.[51]

Enhancing Healthcare Team Outcomes

Portal vein thrombosis is a relatively common presentation in clinical practice. Because the disorder has enormous morbidity and mortality if left untreated, the condition is best managed by a team of interprofessional healthcare professionals of clinicians, nurses, and pharmacists. Nurses and pharmacists should be empowered to make suggestions to the clinician staff in managing these patients, utilizing open communication and shared decision-making. This interprofessional approach will result in the best patient outcomes for portal vein thrombosis. To reduce morbidity, prompt diagnosis and treatment are necessary. Patients treated with early anticoagulation have a 5-year survival of 85%. The acute condition has a much better prognosis than chronic portal vein thrombosis, where the liver function is often compromised. TIPS and open surgical procedures are much less used today because of the availability of percutaneous techniques associated with much fewer complications.

References

[1]

Carneiro C, Brito J, Bilreiro C, Barros M, Bahia C, Santiago I, Caseiro-Alves F. All about portal vein: a pictorial display to anatomy, variants and physiopathology. Insights into imaging. 2019 Mar 21:10(1):38. doi: 10.1186/s13244-019-0716-8. Epub 2019 Mar 21     [PubMed PMID: 30900187]

Level 3 (low-level) evidence

[2]

Sakiani S, Heller T, Koh C. Current and investigational drugs in early clinical development for portal hypertension. Frontiers in medicine. 2022:9():974182. doi: 10.3389/fmed.2022.974182. Epub 2022 Oct 10     [PubMed PMID: 36300180]

[3]

Granger DN, Holm L, Kvietys P. The Gastrointestinal Circulation: Physiology and Pathophysiology. Comprehensive Physiology. 2015 Jul 1:5(3):1541-83. doi: 10.1002/cphy.c150007. Epub     [PubMed PMID: 26140727]

[4]

Salembier A, Verhamme M, Verhamme P, Van Moerkercke W. Acute non-cirrhotic portal vein thrombosis : review. Acta gastro-enterologica Belgica. 2018 Apr-Jun:81(2):318-322     [PubMed PMID: 30024704]

[5]

Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology (Baltimore, Md.). 2000 Mar:31(3):587-91     [PubMed PMID: 10706547]

[6]

Chawla YK, Bodh V. Portal vein thrombosis. Journal of clinical and experimental hepatology. 2015 Mar:5(1):22-40. doi: 10.1016/j.jceh.2014.12.008. Epub 2015 Jan 6     [PubMed PMID: 25941431]

[7]

Naymagon L, Tremblay D, Mascarenhas J, Schiano T. Characteristics, anticoagulation, and outcomes of portal vein thrombosis after intra-abdominal surgery. Surgery. 2021 May:169(5):1175-1181. doi: 10.1016/j.surg.2020.11.016. Epub 2020 Dec 24     [PubMed PMID: 33358635]

[8]

Shoar S, Saber AA, Rubenstein R, Safari S, Brethauer SA, Al-Thani H, Asarian AP, Aminian A. Portomesentric and splenic vein thrombosis (PMSVT) after bariatric surgery: a systematic review of 110 patients. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2018 Jan:14(1):47-59. doi: 10.1016/j.soard.2017.09.512. Epub 2017 Sep 14     [PubMed PMID: 29111221]

Level 1 (high-level) evidence

[9]

Emmi G, Bettiol A, Silvestri E, Di Scala G, Becatti M, Fiorillo C, Prisco D. Vascular Behçet's syndrome: an update. Internal and emergency medicine. 2019 Aug:14(5):645-652. doi: 10.1007/s11739-018-1991-y. Epub 2018 Nov 29     [PubMed PMID: 30499073]

[10]

Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology. 2019 May:156(6):1582-1599.e1. doi: 10.1053/j.gastro.2019.01.265. Epub 2019 Feb 13     [PubMed PMID: 30771355]

[11]

Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N, Sato N, Abe H, Aoki Y, Hoshi T, Hashimoto H. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000 Oct:20(5):366-73     [PubMed PMID: 11092254]

Level 3 (low-level) evidence

[12]

Rabie H, Othman W, Elsabaawy DM, Elshemy EE, Abdelmageed N, Khalaf FA, Bedair HM. Janus Kinase-2 Mutation Associated Portal Vein Thrombosis Complicating Liver Cirrhosis and Hepatocellular Carcinoma. Asian Pacific journal of cancer prevention : APJCP. 2021 Jan 1:22(1):267-275. doi: 10.31557/APJCP.2021.22.1.267. Epub 2021 Jan 1     [PubMed PMID: 33507708]

[13]

Gattini D, Cifuentes LI, Torres-Robles R, Gana JC. Sclerotherapy versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis. The Cochrane database of systematic reviews. 2020 Jan 10:1(1):CD011659. doi: 10.1002/14651858.CD011659.pub2. Epub 2020 Jan 10     [PubMed PMID: 31922266]

Level 1 (high-level) evidence

[14]

Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Naymagon S, Mascarenhas J, Schiano T. The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease. Inflammatory bowel diseases. 2021 Jan 19:27(2):215-223. doi: 10.1093/ibd/izaa053. Epub     [PubMed PMID: 32185400]

[15]

Ma SD, Wang J, Bezinover D, Kadry Z, Northup PG, Stine JG. Inherited thrombophilia and portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Research and practice in thrombosis and haemostasis. 2019 Oct:3(4):658-667. doi: 10.1002/rth2.12253. Epub 2019 Sep 10     [PubMed PMID: 31624785]

Level 1 (high-level) evidence

[16]

How J, Zhou A, Oh ST. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Therapeutic advances in hematology. 2017 Mar:8(3):107-118. doi: 10.1177/2040620716680333. Epub 2016 Dec 8     [PubMed PMID: 28246554]

Level 3 (low-level) evidence

[17]

Kashirin SD, Kozhevnikov VA, Suvorova AV, Khaziev AT, Golovko VI. [A differentiated approach to the diagnosis and treatment of portal hypertension in children]. Vestnik khirurgii imeni I. I. Grekova. 2011:170(5):44-8     [PubMed PMID: 22238965]

[18]

Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, Bombardieri G, De Cristofaro R, De Gaetano AM, Landolfi R, Gasbarrini A. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World journal of gastroenterology. 2010 Jan 14:16(2):143-55     [PubMed PMID: 20066733]

[19]

Boucher AA, Wastvedt S, Hodges JS, Beilman GJ, Kirchner VA, Pruett TL, Hering BJ, Schwarzenberg SJ, Downs E, Freeman M, Trikudanathan G, Chinnakotla S, Bellin MD. Portal Vein Thrombosis May Be More Strongly Associated With Islet Infusion Than Extreme Thrombocytosis After Total Pancreatectomy With Islet Autotransplantation. Transplantation. 2021 Nov 1:105(11):2499-2506. doi: 10.1097/TP.0000000000003624. Epub     [PubMed PMID: 33988346]

[20]

Nawacki Ł, Matykiewicz J, Stochmal E, Głuszek S. Splanchnic Vein Thrombosis in Acute Pancreatitis and Its Consequences. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2021 Jan-Dec:27():10760296211010260. doi: 10.1177/10760296211010260. Epub     [PubMed PMID: 33887991]

[21]

Wang R, Guo X, Tang Y, Qi X. Portal vein thrombosis as the first presentation of paroxysmal nocturnal hemoglobinuria. Drug discoveries & therapeutics. 2022 Sep 17:16(4):200-203. doi: 10.5582/ddt.2022.01033. Epub 2022 Aug 21     [PubMed PMID: 35989282]

Level 2 (mid-level) evidence

[22]

Jabiry-Zieniewicz Z, Dabrowski FA, Suchońska B, Kowalczyk R, Nowacka E, Kociszewska-Najman B, Pietrzak B, Malkowski P, Wielgos M. Pregnancy and delivery in women with esophageal varices due to hepatic vein thrombosis. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2015 Jan:28(2):177-81. doi: 10.3109/14767058.2014.908846. Epub 2014 Apr 29     [PubMed PMID: 24670239]

Level 2 (mid-level) evidence

[23]

van Vroonhoven TJ, Molenaar JC. Distal splenorenal shunt for decompression of portal hypertension in children with cystic fibrosis. Surgery, gynecology & obstetrics. 1979 Oct:149(4):559-60     [PubMed PMID: 483134]

[24]

Lv Y, Bai W, Li K, Wang Z, Guo W, Luo B, Wang J, Wang Q, Wang E, Xia D, Li X, Yuan J, Han N, Niu J, Yin Z, Fan D, Han G. Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study. The American journal of gastroenterology. 2021 Jul 1:116(7):1447-1464. doi: 10.14309/ajg.0000000000001194. Epub     [PubMed PMID: 33630766]

Level 2 (mid-level) evidence

[25]

Buzelé R, Barbier L, Sauvanet A, Fantin B. Medical complications following splenectomy. Journal of visceral surgery. 2016 Aug:153(4):277-86. doi: 10.1016/j.jviscsurg.2016.04.013. Epub 2016 Jun 8     [PubMed PMID: 27289254]

[26]

Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Annals of gastroenterology. 2018 May-Jun:31(3):315-329. doi: 10.20524/aog.2018.0245. Epub 2018 Mar 3     [PubMed PMID: 29720857]

[27]

Pan J, Wang L, Gao F, An Y, Yin Y, Guo X, Nery FG, Yoshida EM, Qi X. Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis. European journal of internal medicine. 2022 Oct:104():21-32. doi: 10.1016/j.ejim.2022.05.032. Epub 2022 Jun 7     [PubMed PMID: 35688747]

Level 1 (high-level) evidence

[28]

Odriozola A, Puente Á, Cuadrado A, Rivas C, Anton Á, González FJ, Pellón R, Fábrega E, Crespo J, Fortea JI. Portal Vein Thrombosis in the Setting of Cirrhosis: A Comprehensive Review. Journal of clinical medicine. 2022 Oct 30:11(21):. doi: 10.3390/jcm11216435. Epub 2022 Oct 30     [PubMed PMID: 36362663]

[29]

Xu X, Guo X, De Stefano V, Silva-Junior G, Goyal H, Bai Z, Zhao Q, Qi X. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatology international. 2019 Jul:13(4):468-481. doi: 10.1007/s12072-019-09951-6. Epub 2019 Jun 7     [PubMed PMID: 31175581]

Level 1 (high-level) evidence

[30]

Liu PH, Huo TI, Miksad RA. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Seminars in liver disease. 2018 Aug:38(3):242-251. doi: 10.1055/s-0038-1666805. Epub 2018 Jul 24     [PubMed PMID: 30041276]

[31]

Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2014 Nov:12(11):1801-12.e7. doi: 10.1016/j.cgh.2014.04.026. Epub 2014 Apr 30     [PubMed PMID: 24793031]

Level 1 (high-level) evidence

[32]

Zhang P, Zhang J, Sun G, Gao X, Wang H, Yan W, Xu H, Zu M, Ma H, Wang W, Lu Z. Risk of Budd-Chiari syndrome associated with factor V Leiden and G20210A prothrombin mutation: a meta-analysis. PloS one. 2014:9(4):e95719. doi: 10.1371/journal.pone.0095719. Epub 2014 Apr 22     [PubMed PMID: 24755609]

Level 1 (high-level) evidence

[33]

Fasola FA, Akere A, Akunwata CU, Onyejelam C, Osundina MA. Protein C Deficiency in a Patient with Anomalous Hemiazygous Vein and Portal Vein Thrombosis. West African journal of medicine. 2021 Apr 23:38(4):387-390     [PubMed PMID: 33903797]

[34]

Hung HC, Lee JC, Cheng CH, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Protein S for Portal Vein Thrombosis in Cirrhotic Patients Waiting for Liver Transplantation. Journal of clinical medicine. 2020 Apr 20:9(4):. doi: 10.3390/jcm9041181. Epub 2020 Apr 20     [PubMed PMID: 32326024]

[35]

Setaka T, Hirano K, Moriya K, Kaneko T, Morita S, Shinkai T, Morishita E, Ichida T. Portal Vein Thrombosis in a Patient with Hereditary Antithrombin Deficiency. Internal medicine (Tokyo, Japan). 2019 Jun 15:58(12):1733-1737. doi: 10.2169/internalmedicine.2295-18. Epub 2019 Feb 25     [PubMed PMID: 30799362]

[36]

Ghumman GM, Ishtiaq R, Avasthi D. Portal Vein Thrombosis in a Patient With Methylenetetrahydrofolate Reductase Gene Mutation and Normal Homocysteine Levels. Cureus. 2021 Sep:13(9):e18225. doi: 10.7759/cureus.18225. Epub 2021 Sep 23     [PubMed PMID: 34722031]

[37]

Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A, Primignani M, Garcia-Pagan JC, Janssen HL, Valla D, European Network for Vascular Disorders of the Liver (EN-Vie). Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology (Baltimore, Md.). 2010 Jan:51(1):210-8. doi: 10.1002/hep.23259. Epub     [PubMed PMID: 19821530]

[38]

Lin J, Zhou KR, Chen ZW, Wang JH, Wu ZQ, Fan J. Three-dimensional contrast-enhanced MR angiography in diagnosis of portal vein involvement by hepatic tumors. World journal of gastroenterology. 2003 May:9(5):1114-8     [PubMed PMID: 12717869]

[39]

Wolter K, Decker G, Kuetting D, Trebicka J, Manekeller S, Meyer C, Schild H, Thomas D. Interventional Treatment of Acute Portal Vein Thrombosis. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2018 Aug:190(8):740-746. doi: 10.1055/a-0631-9265. Epub 2018 Jul 25     [PubMed PMID: 30045398]

[40]

Rosenqvist K, Ebeling Barbier C, Rorsman F, Sangfelt P, Nyman R. Treatment of acute portomesenteric venous thrombosis with thrombectomy through a transjugular intrahepatic portosystemic shunt: a single-center experience. Acta radiologica (Stockholm, Sweden : 1987). 2018 Aug:59(8):953-958. doi: 10.1177/0284185117742683. Epub 2017 Dec 3     [PubMed PMID: 29202584]

[41]

Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. Journal of hepatology. 2021 Aug:75(2):442-453. doi: 10.1016/j.jhep.2021.04.029. Epub 2021 Apr 27     [PubMed PMID: 33930474]

[42]

Harding DJ, Perera MT, Chen F, Olliff S, Tripathi D. Portal vein thrombosis in cirrhosis: Controversies and latest developments. World journal of gastroenterology. 2015 Jun 14:21(22):6769-84. doi: 10.3748/wjg.v21.i22.6769. Epub     [PubMed PMID: 26078553]

[43]

Weinberg EM, Palecki J, Reddy KR. Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis. Seminars in liver disease. 2019 May:39(2):195-208. doi: 10.1055/s-0039-1679934. Epub 2019 Apr 12     [PubMed PMID: 30978730]

[44]

García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP reports : innovation in hepatology. 2020 Aug:2(4):100122. doi: 10.1016/j.jhepr.2020.100122. Epub 2020 May 23     [PubMed PMID: 32671331]

[45]

Levi Sandri GB, Lai Q, Berloco PB, Rossi M. Portal vein thrombosis before liver transplant does not alter postoperative patient or graft survival. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2014 Jun:12(3):238-40     [PubMed PMID: 24907725]

Level 2 (mid-level) evidence

[46]

Potze W, Adelmeijer J, Porte RJ, Lisman T. Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis. Thrombosis research. 2015 May:135(5):1012-6. doi: 10.1016/j.thromres.2015.02.025. Epub 2015 Feb 26     [PubMed PMID: 25746364]

Level 2 (mid-level) evidence

[47]

Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Digestive diseases and sciences. 2016 Jun:61(6):1721-7. doi: 10.1007/s10620-015-4012-2. Epub 2016 Jan 2     [PubMed PMID: 26725062]

[48]

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: Vascular diseases of the liver. Journal of hepatology. 2016 Jan:64(1):179-202. doi: 10.1016/j.jhep.2015.07.040. Epub 2015 Oct 26     [PubMed PMID: 26516032]

Level 1 (high-level) evidence

[49]

Gameiro AF, Robalo Nunes A, Guerra P, Mateus E, Fernandes F. Portal Vein Thrombosis Secondary to Occult Polycythemia Vera. European journal of case reports in internal medicine. 2020:7(12):002003. doi: 10.12890/2020_002003. Epub 2020 Nov 2     [PubMed PMID: 33457359]

Level 3 (low-level) evidence

[50]

Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 2017 Aug:153(2):480-487.e1. doi: 10.1053/j.gastro.2017.04.042. Epub 2017 May 4     [PubMed PMID: 28479379]

Level 1 (high-level) evidence

[51]

Gebreselassie A, Bukhari M, Awan A, Khashab M. Recurrent Biliary Obstruction Secondary to Portal Biliopathy and the Role of Cholangioscopy: A Case Report [corrected]. Cureus. 2018 Jan 9:10(1):e2046. doi: 10.7759/cureus.2046. Epub 2018 Jan 9     [PubMed PMID: 29541567]

Level 3 (low-level) evidence